ABSTRACT
Hollow microcapsules with the shell composed of biodegradable polyelectrolytes modified with the maghemite nanoparticles were fabricated by in situ synthesis. The nanoparticles were synthesized from the iron salt and the base directly on the capsule shells prepared by "layer by layer" technique. An average diameter of the capsule was about 6.7 µm while the average thickness of the capsule shell was 0.9 µm. XRD, HRTEM, Raman and Mössbauer spectroscopy data revealed that the iron oxide nanoparticles have the crystal structure of maghemite γ-Fe2O3. The nanoparticles were highly monodisperse with medium size of 7.5 nm. The Mössbauer spectroscopy data revealed that the nanoparticles have marked superparamagnetic behavior which was retained up to room temperature due to slow spin relaxation. Because of that, the microcapsules can be handled by an external magnetic field. Both these properties are important for target drug delivery. Based on the Mössbauer spectroscopy data, the spin blocking temperatures TB of about 90K was found for the particles with size D≤5 nm and TB≈250 K for particles with D≥6 nm. The anisotropy constants K were determined using the superparamagnetic approximation and in the low temperature approximation of collective magnetic excitation.
Subject(s)
Capsules/chemical synthesis , Magnetite Nanoparticles/chemistry , Capsules/chemistry , Ferric Compounds/chemistry , Microscopy, Electron, Transmission , Particle Size , Spectroscopy, Mossbauer , Spectrum Analysis, Raman , Temperature , X-Ray DiffractionABSTRACT
We studied antiepileptic effects of cortexin administered in doses 0,015, 0,15 and 1,0 mg/kg intraperitoneally in solution or intranasally in the complex with nanoparticles in a model of acute and chronic convulsions in rats induced by pentylenetetrazole. In the model of epileptic status, the long-term preliminary administration of cortexin had no effect on convulsions while in the model of chronic convulsions (temporal epilepsy), cortexin had a marked dose-dependent antiepileptic effect. The influence of cortexin on neuroplasticity and its clinical potential are discussed.
